Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management
ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA.
“ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce our mission to deliver meaningful therapeutic options for diverse patient populations who need alternatives to statins.”
| Moderated Presentations |
| |
Title:
Session:
Location:
Date & Time:
Authors:
Presenter: | Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant
Patients: An Analysis of The Clear Outcomes Trial
1069
Moderated Poster Theatre 06, Posters, Hall E
Saturday, March 28, 2026, 4:18 – 4:25 pm ET
C. Pires Zingano, D. Brennan, M. Li, W. Sasiela, L. Bloedon, S.E.
Nissen, L.J. Laffin
Carolina Pires Zingano, MD (Cleveland Clinic)
|
| | |
Title:
Session:
Location:
Date & Time:
Authors:
Presenter:
| Bempedoic Acid and Cardiovascular Outcomes in Patients with Autoimmune
or Inflammatory Diseases: An Analysis of the Clear Outcomes Trial
1084
Moderated Poster Theater 05, Posters, Hall E
Sunday, March 29, 2026, 9:30 – 9:37 am ET
B. Frison Spiazzi, B. Weber, D. Brennan, L. Bloedon, M. Li, S.E. Nissen, L.J.
Laffin
Bernardo Frison Spiazzi, MD (Cleveland Clinic)
|
| |
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
© 2026 Canjex Publishing Ltd. All rights reserved.